MK-677 (Ibutamoren): Evidence, Mechanism & Legal Status

MK-677 (ibutamoren; also MK-0677, L-163,191) is an oral, once-daily compound marketed and "stacked" alongside injectable GH-releasing peptides as a needle-free way to raise growth hormone and IGF-1.10 Its popularity in fitness and anti-aging circles is enormous; its proven clinical benefit is far narrower than the hype. This monograph separates the biomarker story from the disease-outcome story — and flags, up front, that despite its place in this peptide library, MK-677 is not a peptide.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. MK-677 is not an FDA-approved drug, is not legally compoundable, and is sold only as a "research chemical not for human consumption"; it is prohibited in sport. Dosing figures are reported strictly as seen in the published trial literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is MK-677 and how does it work?

Chemically, MK-677 is a non-peptide small molecule — a spiropiperidine derivative with formula C₂₇H₃₆N₄O₅S and a molecular weight of about 528.67 g/mol, typically supplied as the mesylate salt. It was developed by Merck in the 1990s, and the related candidate LUM-201 was later pursued for pediatric GH-deficiency diagnostics.10 Because it is a small molecule rather than a peptide, it resists gastrointestinal enzymatic degradation and is orally bioavailable — the central practical distinction from injectable GHRPs such as ipamorelin or hexarelin, which are degraded if swallowed.7

Its target is the growth-hormone-secretagogue receptor 1a (GHS-R1a) — the ghrelin receptor — a GPCR expressed in the hypothalamus and anterior pituitary. By activating it, MK-677 amplifies endogenous GH-releasing-hormone tone and suppresses somatostatin, increasing pulsatile GH secretion.7 Crucially, the human dose-ranging data show it works by enhancing the height and trough of pre-existing GH pulses rather than creating new ones, preserving the physiologic pulsatile pattern — in contrast to continuous exogenous GH.1 Because GHS-R1a is also the appetite receptor, MK-677 reproduces ghrelin's orexigenic (appetite-stimulating) effect, a feature absent from selective GHRPs.7 Pharmacologically it has a short plasma half-life (about 4 to 6 hours in animal data) yet a roughly 24-hour effect on IGF-1, permitting once-daily dosing and sustained, round-the-clock GH/IGF-1 elevation; tolerance did not develop even over the 2-year trial.102

What is the evidence by indication?

MK-677 is the rare GH secretagogue where the biomarker claim earns Grade A from genuine RCTs, but the clinically meaningful outcomes were repeatedly null. The two must not be conflated. The table below grades each indication; the registry entry for the related oral-GHS pediatric program can be reviewed at ClinicalTrials.gov NCT04614337.

The biomarker result is the single most reproducible MK-677 finding. In the foundational dose-ranging trial, 32 healthy elderly subjects took placebo or 2/10/25 mg daily; the 25 mg dose raised the 24-hour mean GH concentration by 97 ± 23% and lifted serum IGF-1 from 141 to 265 µg/L within four weeks — restoring it to young-adult levels.1 The pivotal body-composition study — Nass et al., a 2-year, double-blind, placebo-controlled trial in 65 adults aged 60 to 81 at 25 mg/day — increased fat-free mass by 1.1 kg versus a 0.5 kg decline on placebo and improved nitrogen balance during diet-induced catabolism.2 But the gain in lean mass did not translate into improved strength or physical function, and the trial documented a decline in insulin sensitivity sustained over the full two years.2 A separate randomized polysomnography study found bedtime MK-677 increased slow-wave sleep by about 50% in young subjects and REM sleep by about 50% in older subjects.5

The disease endpoints are where MK-677 fails. In the hip-fracture program, Adunsky et al. ran a Phase IIb RCT in 123 elderly patients; IGF-1 rose about 84% and gait speed improved modestly, but most functional measures did not improve — and the data-monitoring committee halted the trial early when 4 of 62 patients on MK-677 (6.5%) versus 1 of 61 on placebo (1.7%) developed congestive heart failure.4 In Alzheimer's disease, Sevigny et al. randomized 563 patients to 25 mg/day or placebo for 12 months; despite robust target engagement (IGF-1 +73% at 12 months), there were no significant differences on any cognitive or functional endpoint, and the authors concluded MK-677 was ineffective at slowing progression.3

What doses appear in the literature?

Reported strictly as information, not a protocol. The standard trial dose is 25 mg orally once daily — the dose used in the aging, Alzheimer's, and hip-fracture RCTs.2 Dose-ranging compared 2, 10, and 25 mg/day: 2 mg was sub-threshold, while 25 mg gave the maximal, young-adult IGF-1 response.1 The sleep studies used 5 mg or 25 mg at bedtime.5 The route is oral — its defining advantage as a small molecule — and once-daily dosing is supported by the roughly 24-hour IGF-1 effect despite a shorter plasma half-life.10 Unlike injectable peptides there is no reconstitution; illicit-market products are oral capsules or solutions of variable, unverified purity sold "not for human consumption." No tachyphylaxis was observed — meaning the metabolic side-effect exposure is also continuous.2

How safe is MK-677?

The dominant metabolic liability is consistent and dose-related: MK-677 reduces insulin sensitivity and raises fasting glucose. Chapman et al. saw fasting glucose rise from 5.4 to 6.8 mmol/L at four weeks, and Nass et al. documented a decline in insulin sensitivity that persisted the full two years — a direct, expected consequence of sustained GH/IGF-1 elevation and the FDA's named concern.12 GH-mediated sodium and water retention cause fluid retention, edema and weight gain across trials.2 The pivotal serious adverse event is the congestive-heart-failure signal that terminated the Adunsky hip-fracture trial early, plausibly from fluid retention unmasking subclinical cardiac dysfunction in a vulnerable elderly population — the small sample limits certainty, but it was enough to stop the trial and shape the FDA's stance.46 As a ghrelin-receptor agonist it also stimulates appetite, and trials reported transient rises in cortisol and prolactin (typically within normal range).1 A theoretical oncologic concern follows from sustained IGF-1 elevation, a standard caution for any GH-axis agent. By class logic it is cautioned against in diabetes or impaired glucose tolerance, heart failure or significant cardiovascular disease, active malignancy, and pregnancy or lactation, and it is banned for competitive athletes.

What is the FDA and WADA status in 2026?

MK-677 has never been approved for any indication in any country. Merck ran genuine Phase II/III trials across roughly six indications — GH deficiency, osteoporosis, hip fracture, sarcopenia, obesity and Alzheimer's — and discontinued development after the efficacy and safety results above.3 The FDA placed ibutamoren mesylate on its Category 2 interim bulk-substances list ("may present significant safety risks," citing potential congestive heart failure).6 The agency referred it to the Pharmacy Compounding Advisory Committee, which on October 29, 2024 voted against adding ibutamoren mesylate to the 503A bulks list — members cited inadequate efficacy/safety evidence and adverse effects including fluid retention, heart failure and hyperglycemia (only one member voted yes, persuaded by the pediatric data). It is therefore not eligible for legal pharmacy compounding, and is sold only as a "research chemical, not for human consumption."79

For athletes the picture is unambiguous. MK-677 is prohibited at all times — in and out of competition — explicitly named "ibutamoren" under WADA category S2.2.4 (Growth Hormone Releasing Factors / GH secretagogues), classed as a non-specified substance carrying the strictest sanctions, and detectable by mass spectrometry.8 It is also on the U.S. Department of Defense prohibited-ingredients list.9

Bottom line. From a root-cause, evidence-first lens, MK-677 is the most rigorously human-tested compound in the GH-secretagogue category — and that rigor is precisely what undermines the marketing. The biomarker story is real and Grade A: oral, once-daily MK-677 dependably restores GH and IGF-1 to young-adult levels and adds a small amount of lean mass. But the clinically meaningful endpoints — strength, functional recovery, Alzheimer's progression — were null in well-powered RCTs, against which sit consistent insulin resistance, fluid retention, appetite gain, and a heart-failure signal that halted a trial. Remember the non-peptide flag: it is a small-molecule ghrelin mimetic, regulated, banned in sport, and not legal for human therapeutic use or compounding in the U.S. in 2026.24